Composition Of Skin External Application For Anti-Aging

ABSTRACT

The present invention relates to an anti-aging composition for external use on skin, and more particularly, to an anti-aging composition for external use on skin comprising at least one of catechins and flavonols as an active ingredient to inhibit decomposition and promote generation or protection at the dermis-epidermis junction.

TECHNICAL FIELD

The present invention relates to an anti-aging composition for externaluse on skin, and more particularly, to an anti-aging composition forexternal use on skin comprising at least one of catechins and flavonolsas an active ingredient to inhibit decomposition and promote generationor protection at the dermis-epidermis junction.

Also, it is possible to obtain synergy effect on anti-aging by using thegreen tea extract in combination with theanine.

BACKGROUND ART

The skin which is a primary barrier of the human body protects organs inthe body from change of temperature and humidity and stimulation fromthe outer environment such as UV rays and pollutants and plays animportant role for homeostasis such as regulation of body temperature.However, excessive physical and chemical stimulation from the outside,UV rays, stress and malnutrition may deteriorate normal functions of theskin and promote skin aging such as elasticity loss, keratinization andwrinkle formation. Particularly, the dermis-epidermis junction isseverely damaged by UV irradiation.

As a result of the observation of change in the skin by aging, it hasbeen found that the change in the structure of the dermis-epidermisjunction such as multiplication and heat insulation already begins inthe skin exposed to UV rays from late twenties. Therefore, it can beexpected that generation of gelatinase (MMP-2, MMP-9) is induced at theepidermis of the human skin exposed to UV rays and associated with thedamage of the dermis-epidermis junction. Further, in the research usingmouse wrinkle model induced by UV-B irradiation for a long period oftime, it has been found that gelatinase formed in the epidermis by UV-Birradiation may cause damage of the dermis-epidermis junction, damage ofdermis and wrinkle formation. Meanwhile, the skin which has been seldomexposed to UV rays does not show such multiplication and heat insulationeven at the advanced age.

Gelatinase (MMP-2, MMP-9) is an enzyme to decompose type IV collagen,type VII collagen and other extracellular matrix which are components ofthe dermis-epidermis junction. According to the analysis according toGelatine zymography and Enzyme Linked Immunosorbent Assay (ELISA), MMP-2and MMP-9 are detected in the UV-exposed epidermis. The activity ofgelatinase in the skin is detected near epidermal stratum basalis andstratum spinosum in the chilled forehead skin. Moreover, gelatinase isdetected in the epidermis of the UV-exposed skin such as the face.Therefore, it is believed that UV rays induce formation of gelatinase inthe epidermal stratum basalis, a part of them participates indestruction of the dermis-epidermis junction and the rest stays in theepidermis and reaches the epidermis.

Upon examination of the wrinkle formation mechanism in the wrinkle modelproduced by irradiating UV rays to a mouse for a long period of time,gelatinase activity is detected throughout the epidermis in the skinexposed to UV-B for a long period of time. The damage of thedermis-epidermis junction is observed from the fifth week of UV-Birradiation and becomes severe upon the seventh and tenth week. Upon thetenth week, heat insulation is observed in the dermis barrier andmultiplication is observed in a part. Upon examination of collagen fiberof the dermal mammillary portion, reduction of fiber density is observedby UV-B irradiation for a long period of time. Therefore, it has beenprovided that the induced gelatinase is involved in damage of thedermis-epidermis junction and collagen decomposition of the mammillarydermis.

When the dermis-epidermis junction is damaged, wrinkle is formed byflattering of the junction, multiplication and heat insulation, and theskin is sagged and is apt to be damaged. Also, by the loss of thecharacteristic barrier function, the dermis-epidermis junction fails tofilter pollutants from the outer environment, whereby noxious materialscan readily infiltrate to the dermis and the skin can be damaged. Inorder to recover the damaged dermis-epidermis junction or maintain it atthe healthy state, its components should be maintained as they are. Thecomponents which is known that whose biosynthesis is decreased, as theage increases, are type IV collagen, type VII collagen and laminin10/11. Laminin 5 does not shown change while the components whosebiosynthesis is increased are gelatinase (MMP-2 and MMP-9) which isknown to be associated with decomposition (Lavker et. Al. J. Invest.Derm. 1979, 73:59-65, Pouliot et. Al. Exp. Dermatol. 2002, 11:387-397).

In order to prevent the skin aging by UV irradiation and outer stressand maintain healthy and elastic skin, there have been efforts tomaintain peculiar function of the skin and activate skin cells toeffectively inhibit the skin aging by using cosmetic compositionsupplemented with physiological activating materials obtained fromanimals, plants and microorganisms.

DISCLOSURE Technical Problem

Accordingly, the present inventors have searched a method foreffectively controlling various factors affecting skin aging and foundthat various change of the junction between the dermis and epidermiscaused by natural aging and photo-aging, including degeneration, heatinsulation and multiplication, can be prevented or recovered by using acomposition for external use on skin comprising at least one ofcatechins and flavonols which are extracted from green tea. Thus, it hasbeen confirmed that catechins or flavonols from the green tea extractcan inhibit the decomposition and promote the generation at thedermis-epidermis junction, thereby strengthening the bonding between thedermis and the epidermis, whereby they can be used in cosmeticpreparations and pharmaceutical compositions for anti-aging.

Also, it has been found that if theanine is combined into the componentsfrom the green tea extract, even when the green tea extract is mixedwith theanine at a low concentration, the combination can show highanti-aging effect without side effects on the skin. On the basis of theabove findings, the present invention has been completed.

Therefore, it is an object of the present invention to provide acomposition for external use on skin with excellent anti-aging effect.

Technical Solution

To accomplish the above objects of the present invention, according tothe present invention, there is provided a composition for external useon skin with excellent anti-aging effect comprising at least one ofcatechins and flavonols as an active ingredient.

Also, in another embodiment of the present invention, there is provideda composition for external use on skin with excellent anti-aging effectcomprising theanine in addition to the above-described components fromthe green tea extract as an active ingredient.

ADVANTAGEOUS EFFECTS

The composition for external use on skin according to the presentinvention comprising at least one of catechins and flavonols of thegreen tea extract as an active ingredient can reduce biosynthesis ofgelatinase (MMP-2, MMP-9) and increase biosynthesis of type IV collagen,type VII collagen and laminin 10/11 to inhibit the decomposition andpromote the generation at the dermis-epidermis junction, thereby protectthe dermis-epidermis junction.

DESCRIPTION OF DRAWINGS

Further objects and advantages of the invention can be more fullyunderstood from the following detailed description taken in conjunctionwith the accompanying drawing, in which:

FIG. 1 is a graph showing the result of the measurement of MMP-1biosynthesis by various test samples.

BEST MODE

The composition for external use on skin according to the presentinvention comprises at least one of catechins and flavonols from thegreen tea extract as an active ingredient.

The catechins used according to the present invention is extracted fromgreen tea and includes epigallocatechin gallate (EGCG), gallocatechingallate (GCG), epicatechin gallate (ECG), catechin gallate (CG),epigallocatechin (EGC), gallocatechin (GC), (−)epicatechin (EC),(+)epicatechin (EC), (−)catechin (CA) and (+)catechin (CA), withpreference being epigallocatechin gallate (EGCG), gallocatechin gallate(GCG), epicatechin gallate (ECG) and catechin gallate (CG) expressed bythe following formulae 1 to 4.

Also, the flavonols used according to the present invention is extractedfrom green tea and includes quercetin, kaempferol and myricetin, withpreference being kaempferol and myricetin, more preference beingmyricetin.

The composition for external use according to the present inventioncomprises 0.001 to 10 wt %, preferably 0.01 to 5 wt % of the activeingredient, based on the total weight of the composition. If the contentis less than 0.001 wt %, it is difficult to expect significant effects,while if the content excesses 10 wt %, it is impossible to formulate thecomposition.

According to another aspect, there is provided a composition forexternal use on skin further comprising theanine as an activeingredient, in addition to the component from the green tea extract.

Theanine is one of amino acids giving savory taste of green tea and haseffect of inhibiting excitation caused by caffeine. In fact, it has beenobserved that human bodies intaking theanine shows increase in a waveappearance showing stabilized and tranquil state of mind (NipponNogeikagaku Kaishi, 1998, 72 (2): 153-157). The theanine used accordingto the present invention may be one selected from L-form which isextracted from green tea, and L-theanine, D-theanine and DL-theaninewhich are chemically synthesized, or may be prepared other methods.

When the composition for external use on skin according to the presentinvention comprises theanine in combination with at least one ofcatechins and flavonols from the green tea extract, it is possible toeffectively and generally improve several symptoms such as wrinkle andsagging. Particularly, the content of at least one of catechins andflavonols from the green tea extract in the composition is determinedfrom the result of in vitro experiments and in vivo experiments and ispreferably 0.0004 to 0.025 wt %, based on the total weight of thecomposition. Here, if the content is less than 0.0004 wt % the componentcannot act as an effective ingredient, while if the content excesses0.025 wt % the improvement of the symptoms is rather deteriorated.

Also, the content of theanine is determined from the result of in vitroexperiments and in vivo experiments and is preferably 0.008 to 2.5 wt %,based on the total weight of the composition. Here, if the content isless than 0.008 wt %, the component cannot act as an effectiveingredient, while if the content excesses 2.5 wt % the improvement ofthe symptoms is rather deteriorated.

Further, the composition for external use on skin according to thepresent invention comprises the green tea extract and theanine in apredetermined mixing ratio. Thus, when the composition contains 0.0004to 0.025 wt % of the green tea extract, catechin to theanine is 1:20 to1:100 for optimal anti-aging effect of skin.

The composition for external use on skin according to the presentinvention prevent and improve skin aging through promotion of collagensynthesis, improvement skin elasticity and improvement of skin wrinkles.

Also, the composition for external use on skin according to the presentinvention activates peroxisome proliferator-activated receptor-alpha(PPAR-α) to inhibit tumor necrosis factor α (TNF-α) and biosynthesis ofMMP-1, thereby inhibiting skin aging.

Peroxisome is one of organelles providing causes of abnormal metabolicfunctions leading hyperlipidemia, diabetes and obesity. For a long time,this organelle has been considered to play a tiny role in the cell.However, according to many recent studies, it has been reported that itplays very important role in control of cellmultiplication/differentiation, control of inflammatory mediators andthe like and widely affects metabolism of oxygen, glucose, lipid andhormones. It has been found that peroxisome affects the formation of thecell membrane and adipocyte as well as insulin sensitivity, throughlipid metabolism and glucose metabolism and plays an important role inaging and tumorigenesis through action on oxidative stress (J Cutan MedSirg 5 (3):231-43, 2001, J Cutan Med Sirg 5 (4):315-22, 2001).

The intensive research on the above-described part for the last 10 yearshas presented several evidences that peroxisome proliferator-activatedreceptos (PPARs), hereinafter referred to as ‘PPAR’), a nuclear hormonereceptor would be a good target for pharmacological approach forabove-described diseases. According to the resent studies, PPARs,particularly PPAR-α, a one of subtypes, play critical roles in promotionof differentiation/inhibition of multiplication of keratinocyte,promotion of dermal barriers through lipid metabolism and inhibition ofinflammation at epidermis of skin and inhibit inflammatory mediatorsformation of PPAR-α and erythema formation by UV irradiation (JID 117(6):1430-6, 2001).

The present inventors have exams general information on biology of thesePPARs and effects and working mechanism of PPAR-α on skin, particularlyrelation with skin aging to find a ligand capable of inducingactivation. As a result, it has been found that by using the compositionfor external use on skin according to the present invention, it ispossible to inhibit inflammation induced by natural aging andphoto-aging, thereby preventing or recovering skin aging. Thus, it hasbeen proved that the composition for external use according to thepresent invention can inhibit expression of matrix metalloproteinase-1,an enzyme to decompose the dermis by inflammation inhibiting mechanismthrough activation of PPAR-α.

The composition for external use according to the present invention isnot particularly limited in its formulation but may be cosmeticcompositions including, for example, skin softener, skin lotion, massagecream, nourishing cream, pack, gel or skin adhesive type cosmeticformulations, or transdermal formulations such as lotion, ointment, gel,cream, patch or spray.

Also, the composition for external use in various formulation types maycomprise the above-described essential components in combination withother components which may be selected by the workers in the art withoutany difficulty according to the formulation type or the purpose of use.

MODE FOR INVENTION

Now, the construction and effect of the present invention will beexplained in detail by Examples and Experimental examples. However, itshould be understood that these examples are only for explanation andthe present invention is not limited thereto.

REFERENCE EXAMPLE 1 Preparation of Green Tea Extract 1

100 g of dried green tea leaves was taken into 10 times ethanol for 12to 15 hours at ambient temperature for extraction, followed byfiltration through filter paper. The filtrate was concentrated at 50° C.at reduced pressure.

REFERENCE EXAMPLE 2 Preparation of Green Tea Extract 2

100 g of dried green tea leaves was taken into 10 times ethanol for 12to 15 hours at ambient temperature for extraction, followed byfiltration through filter paper. The filtrate was concentrated at 50° C.at reduced pressure.

EXPERIMENTAL EXAMPLE 1 Measurement of Inhibiting Effect on Biosynthesisof Gelatinase A (MMP-9) and Gelatinase B (MMP-2) by UV Irradiation

Human keratinocytes were cultured in a 24-well plate type incubator at aconcentration of 10⁴. After 24 hours, the plate was irradiated by UV-Bat 30 mJ/cm². The media were exchanged with new medium containing 10 ppmof each test substance. After 2 days of cultivation, each supernatantwas harvested and subjected to the zymography using gelatine gel toobtain produced MMP-2 and MMP-9, quantities of which were then measuredby a densitometer. The data were calculated as comparative values,referred to 100 of UV control and the result is shown in Table 1.

TABLE 1 Ingredients MMP-2 (%) MMP-9 (%) Myricetin 51 55 EGCG 52 56 GCG53 56 CG 53 55 Green tea extract 1 48 49 Green tea extract 2 61 62 Greentea catechin extract 1 55 59 Green tea catechin extract 2 62 60 Control100 100

From the result of Table 1, it was confirmed that the active ingredientused as an active ingredient in the present invention, myricetin,epigallocatechin gallate (EGCG), gallocatechin gallate (GCG),epicatechin gallate (ECG), catechin gallate (CG), green tea catechinextract and green tea extract reduced biosynthesis of MMP-2 and MMP-9,enzymes to decompose type IV collagen and type VII collagen of dermalmatrix, thereby preventing decomposition of the dermis-epidermisjunction.

EXPERIMENTAL EXAMPLE 2 Measurement of Effect on Biosynthesis of Type IVCollagen in Dermal Cell

Human keratinocytes were cultured in a 24-well plate type incubator at aconcentration of 5×10⁴. The media were exchanged with new mediumcontaining 10 ppm of each test substance. After 24 hours of cultivation,each supernatant was harvested and subjected to the Dot Blot method tomeasure the amount of produced type IV collagen. The data werecalculated as comparative values, referred to 100 of UV control and theresult is shown in Table 2.

TABLE 2 Type IV collagen biosynthesis Ingredients (%) Myricetin 139 EGCG138 GCG 135 CG 134 Green tea extract 1 140 Green tea extract 2 139 Greentea catechin extract 1 145 Green tea catechin extract 2 143 Control 100

From the result of Table 2, it was confirmed that the active ingredientused as an active ingredient in the present invention, myricetin,epigallocatechin gallate (EGCG), gallocatechin gallate (GCG),epicatechin gallate (ECG), catechin gallate (CG), green tea catechinextract and green tea extract increased biosynthesis of type IVcollagen.

EXPERIMENTAL EXAMPLE 3 Measurement of Effect on Biosynthesis of Type VIICollagen in Dermal Cell

Human fibroblasts were cultured in a 24-well plate type incubator at aconcentration of 10⁴. The media were exchanged with new mediumcontaining 10 ppm of each test substance. After 24 hours of cultivation,each supernatant was harvested and subjected to the Dot Blot method tomeasure the amount of produced type VII collagen. The data werecalculated as comparative values, referred to 100 of UV control and theresult is shown in Table 3.

TABLE 3 type VII collagen Ingredients biosynthesis (%) Myricetin 125EGCG 127 GCG 121 CG 124 Green tea extract 1 132 Green tea extract 2 128Green tea catechin extract 1 131 Green tea catechin extract 2 127Control 100

From the result of Table 3, it was confirmed that the active ingredientused as an active ingredient in the present invention, myricetin,epigallocatechin gallate (EGCG), gallocatechin gallate (GCG),epicatechin gallate (ECG), catechin gallate (CG), green tea catechinextract and green tea extract increased biosynthesis of type VIIcollagen.

EXPERIMENTAL EXAMPLE 4 Measurement of Effect on Biosynthesis of Laminin10/11 in Dermal Cell

Human keratinocytes were cultured in a 24-well plate type incubator at aconcentration of 5×10⁴. The media were exchanged with new mediumcontaining 10 ppm of each test substance. After 24 hours of cultivation,each supernatant was harvested and subjected to the Western Blot methodto measure the amount of produced laminin 10/11. The data werecalculated as comparative values, referred to 100 of UV control and theresult is shown in Table 4.

TABLE 4 laminin 10/11 Ingredients biosynthesis (%) Myricetin 132 EGCG137 GCG 131 CG 129 Green tea extract 1 137 Green tea extract 2 133 Greentea catechin extract 1 139 Green tea catechin extract 2 142 Control 100

From the result of Table 4, it was confirmed that the active ingredientused as an active ingredient in the present invention, myricetin,epigallocatechin gallate (EGCG), gallocatechin gallate (GCG),epicatechin gallate (ECG), catechin gallate (CG), green tea catechinextract and green tea extract increased biosynthesis of laminin 10/11.

EXPERIMENTAL EXAMPLE 5 Measurement of Change at Dermis-EpidermisJunction in Nude Mouse

In order to confirm the change at the dermis-epidermis junction by UVirradiation after use of the composition according to the presentinvention, Examples 1 to 9 and Comparative example 1 were prepared in anourishing cream formulation as shown in Table 5 and applied on the backof a nude mouse 5 times per week for 2 weeks. Then, the formulationswere applied 5 times on the back while the back was irradiated with UV 3times per week for 12 weeks. Through biopsy, the change at thedermis-epidermis junction was examined using an electron microscope.

TABLE 5 Com. Example Ex. Ingredients (wt %) 1 1-1 1-2 2 3 4 5 6 7 8 9 1Purified water Bal. Bal. Bal. Bal. Bal. Bal. Bal. Bal. Bal. Bal. Bal.Bal. Myricetin 0.1 0.2 0.5 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 — EGCG — — —0.1 — — — — — — 0.1 — GCG — — — — 0.1 — — — — — 0.1 — CG — — — — — 0.1 —— — — — — Green tea extract 1 — — — — — — 0.1 — — — — — Green teaextract 2 — — — — — — — 0.1 — — — — Green tea catechin extract 1 — — — —— — — — 0.1 — — — Green tea catechin extract 2 — — — — — — — — — 0.1 — —Hydrogenated vegetable oil 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.501.50 1.50 1.50 Stearic acid 0.60 0.60 0.60 0.60 0.60 0.60 0.60 0.60 0.600.60 0.60 0.60 Glycerol stearate 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.001.00 1.00 1.00 1.00 Steary alcohol 2.00 2.00 2.00 2.00 2.00 2.00 2.002.00 2.00 2.00 2.00 2.00 Polyglyceril-10/penta 1.00 1.00 1.00 1.00 1.001.00 1.00 1.00 1.00 1.00 1.00 1.00 stearate/behenyl alcohol/ sodiumstearoyl lactylate Arakidyl behenyl alcohol/ 1.00 1.00 1.00 1.00 1.001.00 1.00 1.00 1.00 1.00 1.00 1.00 arakidyl glucoside Cetylarylalcohol/cetelaryl 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.002.00 glucoside PEG-100 stearate/ 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.501.50 1.50 1.50 1.50 glycerololate/propylene glycol Caprylic and capric11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.00triglyceride Cyclomedicone 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 Preservative, flavor * * * * * * * * * * * * Triethanolamine 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Bal.: balance, *:suitable amount

As a result, when the cosmetic formulations of Examples 1-9 were appliedalong with UV irradiation, there was hardly observed deformation,separation, isolation and multiplication at the dermis-epidermisjunction, as compared to Comparative example. From the result, it wasconfirmed that the active ingredient used as an active ingredient in thepresent invention, myricetin, epigallocatechin gallate (EGCG),gallocatechin gallate (GCG), epicatechin gallate (ECG), catechin gallate(CG), green tea catechin extract and green tea extract reduce wrinkleson skin and strengthen elasticity and the result is shown in Table 6.

Particularly, when myricetin is used in combination withepigallocatechin gallate (EGCG), gallocatechin gallate (GCG),epicatechin gallate (ECG), catechin gallate (CG), green tea catechinextract and green tea extract, the effect was better, as compared to thecase when myricetin is used alone. Also, it was more preferable to usemyricetin at a low concentration in combination with catechin, ascompared to the case when it is used alone at a high concentration.

TABLE 6 Change at the dermis-epidermis junction Example Com. Ex. 1 1-11-2 2 3 4 5 6 7 8 9 1 Multiplication + + + + +/− +/− +/− +/− +/− +/− +/−++++ Heat insulation + + + + +/− +/− +/− +/− +/− +/− +/− ++++ +/−: nochange, +: little, ++: mild, +++: significant, ++++: very significant

EXPERIMENTAL EXAMPLE 6 Measurement of Effect on Biosynthesis of Collagenin Dermal Cell

Human fibroblasts were cultured in a 48-well plate type incubator at aconcentration of 10⁴. The media were exchanged with new medium(theanine: 1, 10, 100 um) containing each test substance of Table 7 at aconcentration of 0.001 μM, 0.01 μM, 0.1 μM, 0.5 μM and 2 μM. After 48hours of cultivation, each supernatant was harvested and subjected toELISA (Takara MK101) to measure the amount of produced pro-collagen. Thedata were calculated as comparative values, referred to 100 of untreatedcontrol and the result is shown in Table 7.

TABLE 7 Collagen Concentration biosynthesis (−) EGCG 0.001 μM 101.4 0.01μM 154.6 0.1 μM 133.8 0.5 μM 155.8 2 μM 78.4 (−) GCG 0.001 μM 98.9 0.01μM 138.3 0.1 μM 147.0 0.5 μM 157.1 2 μM 75.2 (−) ECG 0.001 μM 100.5 0.01μM 181.7 0.1 μM 165.3 0.5 μM 124.5 2 μM 77.8 (−) CG 0.001 μM 104.3 0.01μM 118.5 0.1 μM 124.9 0.5 μM 118.9 2 μM 80.3 Theanine 1 μM 13.5 10 μM132.1 100 μM 167.5

From the result of Table 7, it was confirmed that catechin or theanineincreased biosynthesis of collagen even at a low concentration.

Also, in order to examine the synergic effect of theanine on collagenbiosynthesis, theanine 10 μM was added to catechin at different 4concentrations and the result is shown in Table 8.

TABLE 8 Catechin Collagen concentration biosynthesis (−)EGCG + theanine10 μM 0.01 μM 157.1 0.1 μM 164.6 0.5 μM 168.1 1 μM 132.4 (−)GCG +theanine 10 μM 0.01 μM 158.0 0.1 μM 167.5 0.5 μM 165.8 1 μM 142.3 (−)ECG + theanine 10 μM 0.01 μM 166.3 0.1 μM 180.4 0.5 μM 178.2 1 μM 122.4(−)CG + theanine 10 μM 0.01 μM 120.7 0.1 μM 144.7 0.5 μM 148.0 1 μM113.2

From the result of Table 8, it was confirmed that the optimalconcentration of catechin to theanine 10 μM was 0.1 to 0.5 μM and thus,the optimal content ratio of catechin to theanine was 1:20 to 1:100.

EXPERIMENTAL EXAMPLE 7 Improvement of Wrinkles in Human

In order to confirm the improvement effect of nourishing cream preparedaccording to the compositions of Comparative examples 2 to 7 andExamples 10 to 13 in Table 9, the following procedures were performed.100 women in thirties were classified into 10 groups of 10 members andeach was treated with the formulations of Comparative examples 2 to 7and Examples 10 to 13. Replicas were taken using silicone and thewrinkle state was assayed on a visiometer (SV600, Courage+Khazakaelectronic GmbH, Germany). The result is shown in Table 10. The valuesof Table 10 are averages of the difference between parameters of afterapplication for 8 weeks and before application.

TABLE 9 Ingredients Com. Com. Com. Com. Com. Com. (content; wt %) Ex. 10Ex. 11 Ex. 12 Ex. 13 Ex. 2 Ex. 3 Ex. 4 Ex. 5 Ex. 6 Ex. 7 Purified waterBal. Bal. Bal. Bal. Bal. Bal. Bal. Bal. Bal. Bal. (−)EGCG 0.0025 — — —0.1 — — — 0.5 — (−)GCG — 0.0004 — — — 0.5 — — — 1 (−)ECG — — 0.002 — — —0.1 — — (−)CG — — — 0.025 — — — 0.1 — theanine 0.01 0.01 0.1 2.5 0.010.01 0.1 5.0 5.0 5.0 Hydrogenated 1.50 1.50 1.50 1.50 1.50 1.50 1.501.50 1.50 1.50 vegetable oil Stearic acid 0.60 0.60 0.60 0.60 0.60 0.600.60 0.60 0.60 0.60 Glycerol stearate 1.00 1.00 1.00 1.00 1.00 1.00 1.001.00 1.00 1.00 Stearyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.002.00 2.00 Polyglyceril- 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.001.00 10/penta stearate/ behenyl alcohol/ sodium stearoyl lactylateArakidyl behenyl 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00alcohol/ arakidyl glucoside Cetylaryl 2.00 2.00 2.00 2.00 2.00 2.00 2.002.00 2.00 2.00 alcohol/cetelaryl glucoside PEG-100 stearate/ 1.50 1.501.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 glycerololate/ propylene glycolCaprylic and capric 11.00 11.00 11.00 11.00 11.00 11.00 11.00 11.0011.00 11.00 triglyceride Cyclomedicone 6.00 6.00 6.00 6.00 6.00 6.006.00 6.00 6.00 6.00 Preservative, flavor * * * * * * * * * * Triethanolamine 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Bal.: balance, *: suitableamount

TABLE 10 Result after application for 8 weeks R1 R2 R3 R4 R5 Ex. 10−0.23 −0.24 −0.16 −0.06 −0.04 Ex. 11 −0.22 −0.23 −0.15 −0.04 −0.05 Ex.12 −0.24 −0.25 −0.18 −0.06 −0.04 Ex. 13 −0.25 −0.24 −0.18 −0.05 −0.03Com. Ex. 2 −0.16 −0.18 −0.13 −0.04 −0.03 Com. Ex. 3 −0.16 −0.17 −0.12−0.06 −0.03 Com. Ex. 4 −0.15 −0.15 −0.13 −0.02 −0.04 Com. Ex. 5 −0.16−0.16 −0.12 −0.04 −0.03 Com. Ex. 6 −0.05 −0.08 −0.12 −0.06 −0.04 Com.Ex. 7 −0.08 −0.10 −0.11 −0.05 −0.03 * R1: difference between the highestvalue and the lowest value of the wrinkle contour line, R2: average of 5R1 values of the wrinkle contour line randomly divided into 5 portions,R3: the highest value of the 5 R1 values, R4: average of the differencebetween the peak and the valley on the baseline of the wrinkle contourline, R5: difference between the baseline of the wrinkle contour lineand the wrinkle contour

As shown in Table 10, it was confirmed that the compositions forexternal use comprising catechin and theanine in a predetermined mixingratio according to Examples 10 to 13 showed excellent effect ofimproving skin wrinkle.

EXPERIMENTAL EXAMPLE 8 Improvement of Skin Elasticity in the Human Body

Nourishing creams prepared according to the compositions of Table 9 wereexamined for their effect to improve skin elastic. 100 healthy womenover 30 years old were divided into 10 groups. Each group applied one ofthe nourishing cream of Comparative examples 2 to 7 and Examples 10 to13 on the face twice per day at a temperature of 24-26° C. and ahumidity of 75% for cream for 12 weeks and was examined for skinelasticity using Cutometer SEM 575, (C+K Electronic Co., Germany). Theresult is shown in Table 11. The data of Table 11 are described as R8(R8 (left)-R8 (right)) of the Cutometer SEM 575, in which RS means skinviscoelasticity.

Separately, the members of the groups were asked to answer aquestionnaire for subjective estimation in addition to the mechanicalevaluation. The result is shown in Table 12.

TABLE 11 Tested composition Skin elasticity Example 10 0.38 Example 110.44 Example 12 0.42 Example 13 0.44 Com. Ex. 2 0.35 Com. Ex. 3 0.33Com. Ex. 4 0.32 Com. Ex. 5 0.36 Com. Ex. 6 0.29 Com. Ex. 7 0.30

TABLE 12 Number of respondents Test group Very good Good Fair PoorExample 10 4 3 2 1 Example 11 4 4 1 1 Example 12 4 3 3 0 Example 13 3 51 1 Com. Ex. 2 1 1 6 2 Com. Ex. 3 1 2 4 3 Com. Ex. 4 0 3 4 3 Com. Ex. 51 2 5 2 Com. Ex. 6 1 1 4 3 Com. Ex. 7 1 1 5 3

As shown in Table 11, the groups treated with the compositions ofExamples 10 to 13 comprising catechin and theanine at a lowconcentration showed more increase in the skin elasticity, as comparedto the group treated with the composition of Comparative example.

Meanwhile, it was confirmed through the questionnaire that the skinelasticity was improved by application of the compositions of Examples10 to 13 according to the present invention.

EXPERIMENTAL EXAMPLE 9 Test of Activation of PPAR-α (PeroxisomeProliferator Activated Receptor-Alpha) Playing a Role in Promotion ofDifferentiation/Inhibition of Multiplication of Dermal Cells andPromotion of Lipid Biosynthesis and Prevention of Inflammation

Monkey kidney epithelial cell line CV-1 (ATCC CCL 70) was subcultured ina DMEM medium containing 10% fetal bovine serum treated withcharcol/dextran, which was a phenol red-free medium to remove the effectby estrogen of phenol red. Three different plasmids, each comprising auniversal promoter capable of being expressed in a general culturingconditions and having PPAR-α gene in the down stream, a universalpromoter having PPRE (PPARs Response Element), which is activated bybonding to PPAR-α of ligand bonding type, and firefly luciferase gene,which functions as a reporter and a universal promoter with Renillaluciferase gene attached as a reference were used.

CV-1 cells were distributed in a 24-well plate type incubator at aconcentration of 5×10⁴. After 24 hours cultivation, the 3 differentplasmids were transient transfected. After 24 hours cultivation, theplate was washed with 1×PBS (Phosphate Buffered Saline) and treated withligand candidates at various concentrations. After 24 hours cultivation,the plate was washed with 1×PBS and the cells were lyzed with 1×PLB(Passive Lysis Buffer) and measured for luciferase activity usingDual-Luciferase^(R) Reporter Assay System kit.

In this experiment, the positive control was Wy-14,643 which was knownto be most powerful PPAR-α ligand and the negative control was ethanolwhich was used to dissolve the samples and non-treated group. The resultis shown in Table 13, with the data as comparative values referred to as1.0 of the negative control and the non-treated group.

TABLE 13 Activity of PPAR-α PPAR-α activity Test substances 10 μM 100 μM(−) EGCG 1.0 1.5 (−) GCG 1.1 2.3 (−) ECG 1.1 1.6 (−) CG 1.2 1.6 (−) EGC1.3 1.0 (−) GC 1.1 1.0 (−) EC 1.2 1.2 (+) EC 1.3 1.2 (−) C 1.4 1.2 (+) C1.5 1.4 Gallic acid 1.3 1.7 Caffeine 1.3 1.6 Quercetin 1.7 2.3Kaempferol 1.7 1.4 Theobromine 2.2 4.5 Theophylline 1.4 1.7 Theanine 1.81.9 Rutin hydrate 1.6 1.3 Quinic acid 1.3 1.7 Myricetin 1.7 1.6 Greentea extract 1 1.7 3.2 Green tea extract 2 1.7 2.3 Catechin extract 1 1.74.6 Catechin extract 2 1.9 4.8 Positive control 0.1 μM 1 μM 10 μM 1.52.6 3.8

From the above result, among the various components of green tea, greentea extract 1, green tea extract 2, catechin extract 1, catechin extract2, gallocatechin gallate ((−) GCG), theobromine and quercetin showedsignificant activation of PPAR-α. (−)EGCG, (−)ECG, (−)CG, (+)C, gallicacid, caffeine, kaempferol, theophylline, theanine, quinic acid andmyricetin were followed.

EXPERIMENTAL EXAMPLE 10 Measurement of Inhibition Effect on Biosynthesisof Tumor Necrosis Factor Alpha (TNF-α) by UV Irradiation

Human keratinocytes were cultured in a 12-well plate type incubator at aconcentration of 10⁴. The plate was irradiated by UV-B at 30 mJ/cm². Themedia were exchanged with new medium containing 10 μM of each testsubstance (10 ppm of extract). After 6 to 24 hours of cultivation, thecells were harvested and subjected to ELISA (Pharmingen 555212) todetermine the amount of produced tumor necrosis factor α (TNF-α). As thepositive control, Wy-14,643 was used. The result is shown in Table 14 ascomparative values, referred to 100 of UV control.

TABLE 14 TNF-α Test substances biosynthesis (10 μM) (%) (−) EGCG 35 (−)GCG 27 (−) ECG 32 (−) CG 37 (+) C 40 Gallic acid 36 Caffeine 39Quercetin 27 Kaempferol 41 Theobromine 25 Theophylline 36 Theanine 30Quinic acid 35 Myricetin 36 Positive control 30 Green tea extract 1 25Green tea extract 2 30 Catechin extract 1 15 Catechin extract 2 12

From the result of Table 14, it was confirmed that the green teaextract, the catechin extract and each component of green tea reducedbiosynthesis of tumor necrosis factor alpha by UV irradiation, therebyeffectively preventing or improving dermal inflammation, reduction ofdermal matrix material, deterioration of elasticity and wrinkleformation which may caused by UV irradiation.

EXPERIMENTAL EXAMPLE 11 Measurement of Inhibition Effect on Biosynthesisof Type I Collagenase (MMP-1) by UV Irradiation

Human fibroblasts isolated from the skin of new born baby were culturedin a 48-well plate type incubator at a concentration of 10⁴. after 24hours, the plate was irradiated by UV-A at 15 J/cm² and antibody againsttumor necrosis factor alpha was added thereto in a concentration of 1ug/ml. At the second day of cultivation, the supernatants were harvestedand subjected to ELISA (AP biotech RPN2610) to determine the amount ofproduced type I collagenase. The result is shown in Table 15 ascomparative values, referred to 100 of control which was not treated.

TABLE 15 Treatment group No-Antibody treated group TNF-α treated groupUV-A irradiated 210 134 group TNF-α treated 250 — group Control 100 100

From the result of Table 15, it was confirmed that biosynthesis of typeI collagenase was increased upon treatment of UV-A and the inflammatorymediator TNF-α and the increase of type I collagenase by UV irradiationwas decreased upon treatment of antibody against TNF-α. Thus, it wasconfirmed when the inflammatory mediator TNF-α was increased by UV-Airradiation, type I collagenase was increased, while when theinflammatory mediator was blocked, the biosynthesis of type Icollagenase was decreased.

When fibroblasts from a new born baby were treated with the followingtest substances, PPAR-α activators, the biosynthesis of type Icollagenase was decreased, which was recovered upon treatment of theinflammatory mediator TNF-α.

To describe the experiment method in detail, human fibroblasts isolatedfrom the skin of a new born baby were cultured in a 48-well plate typeincubator at a concentration of 10⁴. After 24 hours, the plate wasirradiated by UV-A at 15 J/cm². The media were exchanged with new mediumcontaining 10 μM or 10 ppm of each test substance and TNF-α was addedthereto in an amount of 10 ng/mL. At the second day of cultivation, thesupernatants were harvested and subjected to ELISA (AP biotech RPN2610)to determine the amount of produced type I collagenase. As the positivecontrol, Wy-14,643 and retinoic acid (RA) were used. The result is shownin Table 16 as comparative values, referred to 100 of negative controlirradiated with UV.

TABLE 16 Type I collagenase Test substances biosynthesis (%) (10 ppm)UV-A irradiated group UV-A + TNF-α treated group (−) EGCG 42 88 (−) GCG43 86 (−) ECG 45 87 (−) CG 53 89 (+) C 45 86 Gallic acid 52 89 Caffeine58 91 Quercetin 35 91 Kaempferol 48 94 Theobromine 32 90 Theophylline 4092 Theanine 60 95 Quinic acid 75 98 Myricetin 52 97 RA 48 86 Wy14643 6092 Green tea extract1 39 88 Green tea extract2 44 89 Catechin 1 38 87Catechin 2 40 89 Negative control 100 124

From the result of Table 16 and FIG. 1, it was confirmed that the greentea extract and each component of green tea reduced biosynthesis of typeIV collagenase by UV irradiation, which was caused by decrease ofbiosynthesis of inflammatory mediators by activation of PPAR-α.

Now, concrete formulations of the anti-aging composition for externaluse on skin according to the present invention will be described.However, the composition for external use on skin according to thepresent invention is not limited thereto.

[Formulation 1] Skin Softener (Skin Lotion)

TABLE 17 Ingredients wt % Purified water Balance Myricetin 0.1 Butyleneglycol 2.0 Propylene glycol 2.0 Carboxyvinylpolymer 0.1 PEG-12nonylphenyl ether 0.2 Polysorbate 80 0.4 Ethanol 10.0  Triethanol amine0.1 Preservative, pigment, flavor Suitable amount

[Formulation 2] Skin Lotion (Milk Lotion)

TABLE 18 Ingredients wt % Purified water Balance Myricetin 0.1 Green teaextract 0.1 Beeswax 4.0 Polysorbate 60 1.5 Sorbitan Sesquiolate 1.5Liquid paraffin 0.5 Caprylic and capric triglyceride 5.0 Glycerine 3.0Butylene glycol 3.0 Propylene glycol 3.0 Carboxyvinylpolymer 0.1Triethanol amine 0.2 Preservative, pigment, flavor Suitable amount

[Formulation 3] Nourishing Cream

TABLE 19 Ingredients wt % Purified water Balance Myricetin 0.1 Green teacatechin 0.1 Beeswax 10.0  Polysorbate 60 1.5 PEG 60 hydrogenated castoroil 2.0 Sorbitan Sesquiolate 0.5 Liquid paraffin 10.0  Squalane 5.0Caprylic and capric triglyceride 5.0 Glycerine 5.0 Putylene glycol 3.0Propylene glycol 3.0 Triethanol amine 0.2 Preservative, pigment, flavorSuitable amount

[Formulation 4] Massage Cream

TABLE 20 Ingredients wt % Purified water Balance Myricetin 0.1epicatechin gallate (ECG) 0.1 Beeswax 10.0  Polysorbate 60 1.5 PEG 60hydrogenated castor oil 2.0 Sorbitan Sesquiolate 0.8 Liquid paraffin40.0  Squalane 5.0 Caprylic and capric triglyceride 4.0 Glycerine 5.0Butylene glycol 3.0 Propylene glycol 3.0 Triethanol amine 0.2Preservative, pigment, flavor Suitable amount

[Formulation 5] Pack

TABLE 21 Ingredients wt % Purified water Balance Myricetin 0.1 Catechingallate (CG) 0.1 Polyvinyl alcohol 13.0  Sodium carboxymethyl cellulose0.2 Glycerine 5.0 Allantoin 0.1 Ethanol 6.0 PEG-12 nonylphenyl ether 0.3Polysorbate 60 0.3 Preservative, pigment, flavor Suitable amount

[Formulation 6] Skin Softener (Skin Lotion)

TABLE 22 Ingredients Content (wt %) Purified water To 100 Green teacatechin 0.0025 Theanine 1 Butylene glycol 2.0 Propylene glycol 2.0Carboxyvinylpolymer 0.1 PEG-12 nonylphenyl ether 0.2 Polysorbate 80 0.4Ethanol 10.0 Triethanol amine 0.1 Preservative, pigment, flavor Suitableamount

[Formulation 7] Skin Lotion (Milk Lotion)

TABLE 23 Ingredients Content (wt %) Purified water To 100 Greenteacatechin 0.0025 Theanine 1 Beeswax 4.0 Polysorbate 60 1.5 SorbitanSesquiolate 1.5 Liquid paraffin 0.5 Caprylic and capric triglyceride 5.0Glycerine 3.0 Butylene glycol 3.0 Propylene glycol 3.0Carboxyvinylpolymer 0.1 Triethanol amine 0.2 Preservative, pigment,flavor Suitable amount

[Formulation 8] Nourishing Cream

TABLE 24 Ingredients Content (wt %) Purified water To 100 Green teacatechin 0.0025 Theanine 1 Beeswax 10.0 Polysorbate 60 1.5 PEG 60hydrogenated castor oil 2.0 Sorbitan Sesquiolate 0.5 Liquid paraffin10.0 Squalane 5.0 Caprylic and capric triglyceride 5.0 Glycerine 5.0Butylene glycol 3.0 Propylene glycol 3.0 Triethanol amine 0.2Preservative, pigment, flavor Suitable amount

[Formulation 9] Massage Cream

TABLE 25 Ingredients Content (wt %) Purified water To 100 Green teacatechin 0.0025 Theanine 1 Beeswax 10.0 Polysorbate 60 1.5 PEG 60hydrogenated castor oil 2.0 Sorbitan Sesquiolate 0.8 Liquid paraffin40.0 Squalane 5.0 Caprylic and capric triglyceride 4.0 Glycerine 5.0Butylene glycol 3.0 Propylene glycol 3.0 Triethanol amine 0.2Preservative, pigment, flavor Suitable amount

[Formulation 10] Pack

TABLE 26 Ingredients Content (wt %) Purified water To 100 Green teacatechin 0.0025 Theanine 1 Polyvinyl alcohol 13.0 Sodium carboxymethylcellulose 0.2 Glycerine 5.0 Allantoin 0.1 Ethanol 6.0 PEG-12 nonylphenylether 0.3 Polysorbate 60 0.3 Preservative, pigment, flavor Suitableamount

[Formulation 11] Skin Softener (Skin Lotion)

TABLE 27 Ingredients wt % Purified water Balance Epigallocatechin (EGCG)0.1 Butylene glycol 2.0 Propylene glycol 2.0 Carboxyvinylpolymer 0.1PEG-12 nonylphenyl ether 0.2 Polysorbate 80 0.4 Ethanol 10.0  Triethanolamine 0.1 Preservative, pigment, flavor Suitable amount

[Formulation 12] Skin Lotion (Milk Lotion)

TABLE 28 Ingredients wt % Purified water Balance Green tea extract 0.1Beeswax 4.0 Polysorbate 60 1.5 Sorbitan Sesquiolate 1.5 Liquid paraffin0.5 Caprylic and capric triglyceride Suitable amount

[Formulation 13] Nourishing Cream

TABLE 29 Ingredients wt % Purified water Balance Kaempferol 0.1 Beeswax10.0  Polysorbate 60 1.5 PEG 60 hydrogenated castor oil 2.0 SorbitanSesquiolate 0.5 Liquid paraffin 10.0  Squalane 5.0 Caprylic and caprictriglyceride 5.0 Glycerine 5.0 Putylene glycol 3.0 Propylene glycol 3.0Triethanol amine 0.2 Preservative, pigment, flavor Suitable amount

INDUSTRIAL APPLICABILITY

The composition for external use on skin according to the presentinvention comprises at least one of catechins and flavonols which arecomponents of green tea as an active ingredient to reduce biosynthesisof gelatinase (MMP-2, MMP-9) and increase biosynthesis of type IVcollagen, type VII collagen and laminin 10/11 thereby inhibitingdecomposition and promoting generation of the dermis-epidermis junctionand protecting the dermis-epidermis junction.

1. An anti-aging composition for external use on skin comprising atleast one of catechins and flavonols as an active ingredient.
 2. Thecomposition according to claim 1, wherein the catechins are selectedfrom the group consisting of (−)EGCG (epigallocatechin gallate), (−)GCG(gallocatechin gallate), (−)ECG (epicatechin gallate), (−)CG (catechingallate), (−)EGC (epigallocatechin), (−)GC (gallocatechin), (−)EC(epicatechin), (+)EC (epicatechin), (−)CA (catechin) and (+)CA(catechin).
 3. The composition according to claim 1, wherein theflavonols are selected from the group consisting of quercetin,kaempferol and myricetin.
 4. The composition according to claim 1,wherein the active ingredient is contained in an amount of 0.001 to 10wt %, based on the total weight of the composition.
 5. The compositionaccording to claim 1, which further comprises theanine as an activeingredient.
 6. The composition according to claim 5, which comprises0.004 to 0.025 wt %, based on the total weight of the composition, of atleast one of catechins and flavonols and 0.008 to 2.5 wt %, based on thetotal weight of the composition, of theanine, in which the content ratioof the at least one of catechins and flavonols to theanine is 1:20 to1:100.
 7. A method of promoting biosynthesis of collagen comprisingadministering to a subject the composition of claim
 1. 8. A method ofreducing wrinkles comprising administering to a subject the compositionof claim
 1. 9. A method of improving skin elasticity comprisingadministering to a subject the composition of claim
 1. 10. A method ofactivating peroxisome proliferator-activated receptors-alpha (PPAR-α)comprising administering to a subject the composition of claim
 1. 11. Amethod of inhibiting inflammation comprising administering to a subjectthe composition of claim
 1. 12. A method of inhibiting expression ofMMP-1 comprising administering to a subject the composition of claim 1.13. A method of inhibiting tumor necrosis factor α (TNF-α) comprisingadministering to a subject the composition of claim 1.